Protagonist Therapeutics Inc (PTGX)
41.65
+1.00
(+2.46%)
USD |
NASDAQ |
Nov 21, 16:00
41.69
+0.04
(+0.10%)
After-Hours: 20:00
Protagonist Therapeutics Profit Margin (Quarterly): -710.4% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -710.4% |
| June 30, 2024 | -734.7% |
| March 31, 2024 | 81.32% |
| December 31, 2023 | 45.56% |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -4.78K% |
| March 31, 2022 | -81.37% |
| December 31, 2021 | -428.3% |
| September 30, 2021 | -328.6% |
| June 30, 2021 | -1.36K% |
| March 31, 2021 | -387.8% |
| Date | Value |
|---|---|
| December 31, 2020 | -334.3% |
| September 30, 2020 | -59.20% |
| June 30, 2020 | -312.4% |
| March 31, 2020 | -550.6% |
| December 31, 2019 | -643.7% |
| September 30, 2019 | -396.3% |
| June 30, 2019 | |
| March 31, 2019 | -904.0% |
| December 31, 2018 | -589.2% |
| September 30, 2018 | -142.8% |
| June 30, 2018 | -74.21% |
| March 31, 2018 | -71.06% |
| December 31, 2017 | -27.05% |
| September 30, 2017 | -54.95% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-4.78K%
Minimum
Jun 2022
81.32%
Maximum
Mar 2024
-705.6%
Average
-387.8%
Median
Mar 2021
Profit Margin (Quarterly) Benchmarks
| Johnson & Johnson | 11.99% |
| Assembly Biosciences Inc | -140.4% |
| Precision BioSciences Inc | -2.85K% |
| Entrada Therapeutics Inc | -71.70% |
| NovaBay Pharmaceuticals Inc | -49.65% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 37.59% |
| Return on Assets | 33.69% |
| Return on Invested Capital | 37.59% |
| Operating Margin (Quarterly) | -886.7% |
| Return on Net Operating Assets | 231.6% |